{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/palliative-care-dyspnoea/management/covid-19/","result":{"pageContext":{"chapter":{"id":"9983f052-047c-5346-adfc-b741909ce269","slug":"covid-19","fullItemName":"Scenario: COVID-19","depth":2,"htmlHeader":"<!-- begin field f7aabd9e-b493-4078-bd81-ab9500b0e8b3 --><h2>Scenario: COVID-19 Management</h2><!-- end field f7aabd9e-b493-4078-bd81-ab9500b0e8b3 -->","summary":"Covers management when considering the possibility of COVID-19.","htmlStringContent":"<!-- begin item cd83deae-83ee-4925-932c-ab9500b0e859 --><!-- begin field 2a4b5d39-259f-49ff-9706-acbc015b15b9 --><p>From birth onwards.</p><!-- end field 2a4b5d39-259f-49ff-9706-acbc015b15b9 --><!-- end item cd83deae-83ee-4925-932c-ab9500b0e859 -->","topic":{"id":"20d4363b-caf3-55a9-beed-09266efa45f4","topicId":"73af552e-909d-456c-86d1-11f7a65040d8","topicName":"Palliative care - dyspnoea","slug":"palliative-care-dyspnoea","lastRevised":"Last revised in November 2020","chapters":[{"id":"0614f3a6-7238-5427-b059-9195b0cc2aa1","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"738e7584-0909-59c3-bd54-43100aed01fe","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"ea721a0d-cda2-5620-8e3f-61e76920b9b3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"83260a2e-73f3-5abd-b049-c307d85d2cff","slug":"changes","fullItemName":"Changes"},{"id":"460710fb-be39-5a74-8adf-44beac90510f","slug":"update","fullItemName":"Update"}]},{"id":"a2422ca0-3b24-5c6e-81d8-07d257fdd44a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2753bf62-a22c-5fb2-936c-554ef07426d4","slug":"goals","fullItemName":"Goals"},{"id":"65f25469-16d4-5c7f-b7bc-a6698ca61164","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"52a827c5-48de-5c0c-8dce-6c7eeeab720d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"cd3e39be-06ce-5750-a1f7-cbc06bb58756","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"50c51a08-6607-5699-96a8-d66cb532d2c5","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"05dc5599-43b4-5340-841b-3b3208f4b947","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"1fd04fd1-0023-5c48-9785-d9a54c7e2eb0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5a84982b-be4e-5901-a577-110f09001119","slug":"definition","fullItemName":"Definition"},{"id":"dab82422-38f4-5a30-b0db-ad2cbf33c2ab","slug":"prevalence-of-dyspnoea-in-palliative-care","fullItemName":"Prevalence of dyspnoea in palliative care"},{"id":"ea086054-ae8f-5666-9159-99b04676d230","slug":"causes-of-dyspnoea","fullItemName":"Causes of dyspnoea"},{"id":"c2601cd4-69b1-563f-870a-8110f4c24103","slug":"complications-of-dyspnoea","fullItemName":"Complications of dyspnoea"}]},{"id":"db288340-b73c-59b1-a8ba-4baec577b887","fullItemName":"Management","slug":"management","subChapters":[{"id":"62ed0387-08f9-5656-8079-a5fffee537f4","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"cdb4ccb3-9b96-5651-9950-6e2e0b8f4da0","slug":"symptomatic-treatment","fullItemName":"Scenario: Symptomatic treatment"},{"id":"5b9d65e3-1fc3-558d-a95e-5e4ff147c7d7","slug":"known-cause-of-dyspnoea","fullItemName":"Scenario: Known cause of dyspnoea"},{"id":"3b6b57e5-ba14-5311-bbf3-d996401c7dc6","slug":"end-of-life-care","fullItemName":"Scenario: End of life care"},{"id":"9983f052-047c-5346-adfc-b741909ce269","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"08f118cb-d39f-532d-b39f-fa97739c656d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"22221f0a-e6f8-5976-bf6c-1024268816e0","slug":"oxygen","fullItemName":"Oxygen"},{"id":"25b01dc5-45e8-563d-872f-cfec63e33029","slug":"opioids","fullItemName":"Opioids"},{"id":"b7f561a2-0802-545a-b7d1-db218387a6e5","slug":"benzodiazepines","fullItemName":"Benzodiazepines"}]},{"id":"9f0bdd3b-82e3-5cbb-908f-d36a887457a8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5c3c7cfe-04b9-5ac4-9255-be56a20c7b5c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"3aa322d7-2279-512c-93a7-55426d21da21","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b889ecee-814d-5e79-b596-a024fbee0acf","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7e27fb69-52fd-5ddc-8f84-6164bb8615d0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c1800f44-6de2-534a-a4ff-32b8b5cf6e24","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6b7633c0-45a5-5a2e-b564-f185c2b9ef5f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2d28faa0-4a5f-565b-a431-6339d01f6e91","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"db288340-b73c-59b1-a8ba-4baec577b887","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"ba391c3b-67b7-501b-bbc4-f45dc8c63b08","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 3e000d66-e58d-4e2c-b6bc-ab9500b0e8b5 --><h3>How should my management vary when considering the possibility of COVID-19?</h3><!-- end field 3e000d66-e58d-4e2c-b6bc-ab9500b0e8b5 -->","summary":null,"htmlStringContent":"<!-- begin item 98ee6d06-dd8d-4648-a8b4-ab9500b0e8b5 --><!-- begin field da8d6ff4-92bb-4746-a9e6-ab9500b0e8b5 --><ul><li class=\"MsoNormal\">For people who are in the palliative phase of their illness and where there is also the possibility that they have contracted COVID-19, breathlessness may become a challenging symptom to manage.   </li><li class=\"MsoNormal\">Firstly assess whether there are any reversible causes of breathlessness, for example, pulmonary oedema.<ul><li class=\"MsoNormal\">For people with a potential diagnosis of pneumonia see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chest-infections-adult/\">Chest infections - adult</a>.</li></ul></li><li class=\"MsoNormal\">Consider whether anxiety is in part responsible for the symptom of breathlessness, as anxiety can be a complicating factor which further exacerbates breathlessness.</li><li class=\"MsoNormal\">The following strategies may help to manage breathlessness:<ul><li class=\"MsoNormal\">Keep the room cool.</li><li class=\"MsoNormal\">Encourage relaxation and breathing techniques and changing body positioning.</li><li class=\"MsoNormal\">Encourage people who are self-isolating alone to improve air circulation by opening a window or door (do <em style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">not</em> use a fan because this can spread infection).</li><li class=\"MsoNormal\">Where oxygen is available, consider a trial of oxygen therapy and assess whether breathlessness improves.</li></ul></li><li class=\"MsoNormal\">Controlled breathing techniques include positioning, pursed-lip breathing, breathing exercises and coordinated breathing training.<ul><li class=\"MsoNormal\">In pursed-lip breathing, people inhale through their nose for several seconds with their mouth closed, then exhale slowly through pursed lips for 4 to 6 seconds. This can help to relieve the perception of breathlessness during exercise or when it is triggered.</li><li class=\"MsoNormal\">Relaxing and dropping the shoulders reduces the 'hunched' posture that comes with anxiety.</li><li class=\"MsoNormal\">Sitting upright increases peak ventilation and reduces airway obstruction.</li><li class=\"MsoNormal\">Leaning forward with arms bracing a chair or knees and the upper body supported has been shown to improve ventilatory capacity.</li><li class=\"MsoNormal\">Breathing retraining aims to help the person regain a sense of control and improve respiratory muscle strength. Physiotherapists and clinical nurse specialists can advise people to learn how to do this (bearing in mind that this support may need to be done remotely).</li></ul></li><li class=\"MsoNormal\">Consider an opioid and benzodiazepine combination (see Tables 4 and 5) for people with COVID-19 who:<ul><li class=\"MsoNormal\">Are at the end of life <em>and</em></li><li class=\"MsoNormal\">Have moderate to severe breathlessness <em>and</em></li><li class=\"MsoNormal\">Are distressed.</li></ul></li><li class=\"MsoNormal\">Consider concomitant use of an antiemetic and a regular stimulant laxative. Please note that the time of publication (April 2020), opioids and benzodiazepines do not have a UK marketing authorisation for moderate to severe breathlessness.</li></ul><p><strong>Table 4. </strong>End-of-life treatments for managing breathlessness for people aged 18 years and over</p><table class=\"MsoNormalTable\" style=\"width: 100.0%; border-collapse: collapse; mso-yfti-tbllook: 1184;\" border=\"1\" width=\"100%\" cellspacing=\"0\" cellpadding=\"0\"><thead><tr style=\"mso-yfti-irow: 1;\"><td style=\"padding: 4.5pt 4.5pt 4.5pt 4.5pt;\" valign=\"top\"><p class=\"MsoNormal\"><strong>Clinical scenario</strong></p></td><td style=\"padding: 4.5pt 4.5pt 4.5pt 4.5pt;\" valign=\"top\"><p class=\"MsoNormal\"><strong>Treatment</strong></p></td></tr><tr style=\"mso-yfti-irow: 2;\"><td style=\"padding: 4.5pt 4.5pt 4.5pt 4.5pt;\" valign=\"top\"><p class=\"MsoNormal\"><strong>Opioid naive</strong> (not currently taking opioids) and able to swallow</p></td><td style=\"padding: 4.5pt 4.5pt 4.5pt 4.5pt;\" valign=\"top\"><p class=\"MsoNormal\"><strong>Oral treatment</strong></p><p class=\"MsoNormal\">Morphine sulfate immediate-release 2.5 mg to 5 mg every 2 to 4 hours as required <em>or</em></p><p class=\"MsoNormal\">morphine sulfate modified-release 5 mg twice a day, increased as necessary (maximum 30 mg daily).</p></td></tr><tr style=\"mso-yfti-irow: 3;\"><td style=\"padding: 4.5pt 4.5pt 4.5pt 4.5pt;\" valign=\"top\"><p class=\"MsoNormal\"><strong>Already taking regular opioids</strong> for other reasons (for example, pain relief)</p></td><td style=\"padding: 4.5pt 4.5pt 4.5pt 4.5pt;\" valign=\"top\"><p class=\"MsoNormal\"><strong>Oral treatment</strong></p><p class=\"MsoNormal\">Morphine sulfate immediate-release 5 mg to 10 mg every 2 to 4 hours as required<em> or</em></p><p class=\"MsoNormal\">one twelfth of the 24-hour dose for pain, whichever is greater.</p></td></tr><tr style=\"mso-yfti-irow: 4;\"><td style=\"padding: 4.5pt 4.5pt 4.5pt 4.5pt;\" valign=\"top\"><p class=\"MsoNormal\"><strong>Unable to swallow</strong></p></td><td style=\"padding: 4.5pt 4.5pt 4.5pt 4.5pt;\" valign=\"top\"><p class=\"MsoNormal\"><strong>Parenteral treatment</strong></p><p class=\"MsoNormal\">Morphine sulfate 1 mg to 2 mg subcutaneously every 2 to 4 hours as required, increasing the dose as necessary.</p><p class=\"MsoNormal\">If needed frequently (more than twice daily), a subcutaneous infusion via a syringe driver may be considered (if available), starting with morphine sulfate 10 mg over 24 hours.</p></td></tr><tr style=\"mso-yfti-irow: 5; mso-yfti-lastrow: yes;\"><td style=\"padding: 4.5pt 4.5pt 4.5pt 4.5pt;\" valign=\"top\"> </td><td style=\"padding: 4.5pt 4.5pt 4.5pt 4.5pt;\" valign=\"top\"><p class=\"MsoNormal\"><strong>Special considerations</strong></p><p class=\"MsoNormal\">If estimated glomerular filtration rate (eGFR) is less than 30 ml per minute, use equivalent doses of oxycodone instead of morphine sulfate.</p><p class=\"MsoNormal\">Consider concomitant use of an antiemetic (such as haloperidol) and a regular stimulant laxative (such as senna).</p><p class=\"MsoNormal\">Continue with non-pharmacological strategies for managing breathlessness when starting an opioid.</p><p class=\"MsoNormal\">Opioid patches should not routinely be used in people who are opioid naive because of the time it takes for the medicine to get to steady state for clinical effect and the high morphine equivalence.</p><p class=\"MsoNormal\"><strong>Add a benzodiazepine if required</strong></p><p class=\"MsoNormal\">For breathlessness and anxiety: lorazepam 0.5 mg sublingually when required (maximum 4 mg daily).</p><p class=\"MsoNormal\">Reduce the dose to 0.25 mg to 0.5 mg in elderly or debilitated people (maximum 2 mg in 24 hours).</p><p class=\"MsoNormal\">For associated agitation or distress: midazolam 2.5 mg to 5 mg subcutaneously when required.</p><p class=\"MsoNormal\">Sedation and opioid use should not be withheld because of a fear of causing respiratory depression.</p></td></tr></thead></table><ul><li class=\"MsoNormal\">Dosages may need to be adjusted because some people dying of COVID-19 may need higher doses to achieve symptom relief. Others may need lower doses because of their size or frailty.</li><li class=\"MsoNormal\">NICE advises that you should seek specialist advice for people aged under 18 years.</li></ul><p><strong>Table 5. </strong>Treatments in the last days and hours of life for managing breathlessness for people aged 18 years and over</p><table class=\"MsoNormalTable\" style=\"width: 100.0%; border-collapse: collapse; mso-yfti-tbllook: 1184;\" border=\"1\" width=\"100%\" cellspacing=\"0\" cellpadding=\"0\"><thead><tr style=\"mso-yfti-irow: 1;\"><td style=\"padding: 4.5pt; width: 29.1222%;\" valign=\"top\"><p class=\"MsoNormal\"><strong>Treatment </strong></p></td><td style=\"padding: 4.5pt; width: 70.7957%;\" valign=\"top\"><p class=\"MsoNormal\"><strong>Dosage</strong></p></td></tr><tr style=\"mso-yfti-irow: 2;\"><td style=\"padding: 4.5pt; width: 29.1222%;\" valign=\"top\"><p class=\"MsoNormal\"><strong>Opioid</strong></p></td><td style=\"padding: 4.5pt; width: 70.7957%;\" valign=\"top\"><p class=\"MsoNormal\">Morphine sulfate 10 mg over 24 hours via a syringe driver, increasing stepwise to morphine sulfate 30 mg over 24 hours as required.</p></td></tr><tr style=\"mso-yfti-irow: 3;\"><td style=\"padding: 4.5pt; width: 29.1222%;\" valign=\"top\"><p class=\"MsoNormal\"><strong>Benzodiazepine</strong> if required in addition to opioid</p></td><td style=\"padding: 4.5pt; width: 70.7957%;\" valign=\"top\"><p class=\"MsoNormal\">Midazolam 10 mg over 24 hours via the syringe driver, increasing stepwise to midazolam 60 mg over 24 hours as required.</p></td></tr><tr style=\"mso-yfti-irow: 4; mso-yfti-lastrow: yes;\"><td style=\"padding: 4.5pt; width: 29.1222%;\" valign=\"top\"><p class=\"MsoNormal\"><strong>Add parenteral</strong> <strong>morphine or midazolam</strong> if required</p></td><td style=\"padding: 4.5pt; width: 70.7957%;\" valign=\"top\"><p class=\"MsoNormal\">Morphine sulfate 2.5 mg to 5 mg subcutaneously as required.</p><p class=\"MsoNormal\">Midazolam 2.5 mg subcutaneously as required.</p></td></tr></thead></table><p class=\"MsoNormal\"> </p><!-- end field da8d6ff4-92bb-4746-a9e6-ab9500b0e8b5 --><!-- end item 98ee6d06-dd8d-4648-a8b4-ab9500b0e8b5 -->","subChapters":[{"id":"ec3961c3-976a-57d8-abcd-181074e4f8b7","slug":"basis-for-recommendation-358","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e65ba4d9-8255-477f-9120-ab9500b0e8b7 --><h4>Basis for recommendation</h4><!-- end field e65ba4d9-8255-477f-9120-ab9500b0e8b7 -->","summary":null,"htmlStringContent":"<!-- begin item 3582bb33-ea9f-496d-a6fa-ab9500b0e8b7 --><!-- begin field 927797bb-4e57-40c3-9992-ab9500b0e8b7 --><p class=\"MsoNormal\">These recommendations are based on the National Institute for Health and Care Excellence (NICE) <em>COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/palliative-care-dyspnoea/references/\">NICE, 2020</a>].</p><!-- end field 927797bb-4e57-40c3-9992-ab9500b0e8b7 --><!-- end item 3582bb33-ea9f-496d-a6fa-ab9500b0e8b7 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}